PM,
I really am not convinced that most BP's are dedicated on advancing personalized products. I do believe they want into the earnings potential of our vaccine, but I don't know that they'll devote a great effort to expanding it. I would much rather have a partnership with one of them, that would give us all the money necessary to advance the science, and they'd be there to assist us, but a dedicated team would continue to work on it.
If we were bought out, I would hope that the buyer would keep NWBO operating as a wholly owned subsidiary of the BP rather than rolling it into the parent company. That model has worked very well for Roche which has many such companies, like Genentech, that continue to operate somewhat independently though wholly owned by Roche. On more than one occasion they spin them off, maintaining a controlling interest, then reacquire them, both shareholders and Roche have done well in this scenario.
Most of the creative work in medical research is being done far more in tiny biotech's and research institutions than in BP's. The BP's influence Congress and the FDA and have been able to make tremendous profits largely based on products developed by others that they acquire, or partner with and take on production, distribution and sales. It's sad, but BP is far more interested in maintaining their patented blockbuster drugs by tweaking them to extend the patents rather than developing new technologies. They let the tiny biotech's and research institutions do the really big breakthroughs then acquire them. They justify the high drug prices by contributing so much to Congress that they won't seriously investigate what they're doing.
I would frankly be uncertain if NWBO was acquired by BP if DCVax-Direct would be in the clinic in a timely way, if at all. In a partnership scenario I believe it would be back in the clinic by next year at the latest.
Gary
News 
Market Data 
Discover 
